Asceneuron

Asceneuron

EPFL Innovation Park, Lausanne
Submit review

Company portrait


Asceneuron is an emerging biotech company specializing in the discovery and development of groundbreaking small molecule therapeutics for neurodegenerative diseases


Mission

We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases.

To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP).

History

Asceneuron was founded in 2012 through a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures.

Our executive management team combines research and development excellence with business and fundraising experience to bring innovation to patients. Our highly skilled scientists have extensive experience in all aspects of the drug discovery value chain. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer’s Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.

Asceneuron pursues a semi-virtual operating model. Our unique biochemical assays, biomarker discovery activities and pharmacology models are pursued in-house, while we collaborate with leading contract research organizations for other activities such as medicinal chemistry. Asceneuron operates in a state-of-the-art facility at the EPFL Innovation Park in Lausanne, Switzerland, in proximity to leading academic institutions in the Lake Geneva area.

Our lead product, an O-GlcNAcase inhibitor which has been demonstrated to modulate tau pathology in preclinical studies, has entered human clinical testing in healthy volunteers. The O-GlcNAcase inhibitor is being developed for the orphan tauopathy Progressive Supranuclear Palsy (PSP).


Job offers


There are no vacancies at the moment.

Keep an eye on this company by adding it to your Favorites.

Reviews


No reviews yet
Help other job seekers and be the first one to write a review.
Asceneuron
EPFL Innovation Park
Lausanne

Industry

Biotechnology / Chemistry / Pharmaceutical

Year of foundation

2012
This website uses cookies to ensure you receive the best service. Further information can be found in our Terms and Conditions and in the Privacy Policy.